Stereotactic Ablative Radiotherapy for Head and Neck Cancer

(SUPPRESS Trial)

Recruiting at 1 trial location

Overseen By Mom Phat

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Disqualifiers: Pregnancy, Breastfeeding, Spinal cord compression, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: Duration not specified

46 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if adding a precise radiation treatment, called stereotactic ablative radiotherapy (also known as Stereotactic Body Radiotherapy or Stereotactic Radiosurgery), benefits people whose head and neck cancer has spread and worsened in specific areas during other treatments. Participants will either continue with their current cancer treatment plan or receive this targeted radiation in addition to it. This trial may suit individuals with head and neck cancer that has spread to 1-5 spots outside the head and neck, particularly if these spots have worsened despite ongoing treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important findings.

Will I have to stop taking my current medications?

The trial does not require you to stop taking your current medications. In fact, it specifies that participants will continue their current systemic therapy while receiving the new treatment.

What prior data suggests that stereotactic ablative radiotherapy is safe for treating head and neck cancer?

Research has shown that stereotactic ablative radiotherapy (SABR) is generally safe and well-tolerated for treating cancer. Studies indicate that serious side effects occur in less than 10% of cases. SABR is a precise and non-invasive treatment, often performed without requiring a hospital stay. It effectively controls tumors and succeeds in many cases. Overall, it offers a promising option with manageable risks for patients with certain types of cancer. ^{1 2 3 4 5}

Why are researchers excited about this study treatment for head and neck cancer?

Stereotactic Ablative Radiotherapy (SABR) is unique because it offers a highly targeted approach to treating head and neck cancer, focusing on oligoprogressive lesions with precision. Unlike traditional radiotherapy that may affect a broader area, SABR pinpoints the cancerous spots with high doses of radiation, potentially reducing damage to surrounding healthy tissue. Researchers are excited about SABR because it can be used alongside existing systemic therapies, potentially enhancing their effectiveness while minimizing side effects. This targeted approach could mean shorter treatment times and improved quality of life for patients.

What evidence suggests that this trial's treatments could be effective for head and neck cancer?

Research has shown that stereotactic ablative radiotherapy (SABR), which participants in the experimental arm of this trial may receive, can effectively treat certain cancers. In previous studies, 1-year survival rates after SABR ranged from 40% to 55%. One study found that 80.1% of patients survived 1 year, and 60.7% survived 2 years, although the quality of these studies varied. SABR precisely targets small areas, which is beneficial when cancer is near important organs. Additionally, the treatment usually has a low rate of severe side effects, often less than 10%. These findings suggest that SABR can be a promising option for treating head and neck cancers that have not spread widely. Participants in the standard arm will receive standard care treatments, which may include switching to subsequent systemic therapy, best supportive care, or continuing the current systemic line. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

Adults over 18 with metastatic head and neck cancer who've seen their disease progress on current systemic treatments. They must have a decent performance status, meaning they can carry out daily activities with varying degrees of assistance. The trial is for those with limited progression in up to 5 lesions that are less than 5cm and spread across no more than 3 organs.

Inclusion Criteria

Ability to provide written informed consent

My cancer has spread to 1-5 spots outside the brain, affecting up to 3 organs, and is under 5cm.

I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

Pregnancy or breastfeeding

I have spinal cord compression.

My cancer has spread to my digestive system.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to either standard of care or receive stereotactic ablative radiotherapy to oligoprogressive lesions while continuing current systemic therapy

Duration not specified

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years

What Are the Treatments Tested in This Trial?

Interventions

• Experimental arm
• Standard arm

Trial Overview

This phase II trial tests if using Stereotactic Ablative Radiotherapy (SABR) on up to five small progressing cancer spots while continuing current systemic therapy is better compared to just switching therapies or supportive care as decided by the doctor.

How Is the Trial Designed?

Group I: Experimental SABR arm Experimental Treatment 1 Intervention

Definitive SABR to oligoprogressive lesions + continue current systemic therapy

Group II: Standard of care Active Control 1 Intervention

Switch to subsequent systemic therapy line, best supportive care or continue current systemic line

Experimental arm is already approved in European Union, United States, Canada for the following indications:

Approved in European Union as Stereotactic Ablative Radiotherapy (SABR) for:

• Lung cancer
• Liver cancer
• Spinal cord tumors
• Cancers in the lymph nodes
• Metastatic disease

Approved in United States as Stereotactic Body Radiotherapy (SBRT) for:

• Tumors in the lungs, spine, liver, neck, lymph nodes or other soft tissues

Approved in Canada as Stereotactic Body Radiotherapy (SBRT) for:

• Similar to those in the US and EU, specific indications may vary by province

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials

389

Recruited

143,000+

Published Research Related to This Trial

Stereotactic Body Radiotherapy (SBRT) demonstrated effective local control rates of 78% at one year and 67% at two years for head and neck skin cancer patients, particularly in a high-risk group of 106 medically unfit patients with advanced disease.

The treatment was associated with manageable toxicity, as 31% of patients experienced acute grade 3 or higher side effects, primarily dermatitis, while only 8% had late grade 3 or higher toxicities, indicating that SBRT is a viable option for patients who cannot undergo standard treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic body radiotherapy for head and neck skin cancer. Voruganti, IS., Poon, I., Husain, ZA., et al.[2022]

Stereotactic body radiation therapy (SBRT) demonstrated a 77% overall response rate in treating head-and-neck cancers, with significant tumor volume reduction observed in patients, indicating its efficacy as a treatment option.

The treatment showed promising tumor control rates of 83.3% for primary tumors and 60.6% for recurrent tumors, with median overall survival times of 28.7 months for primary, 6.7 months for recurrent, and 5.6 months for metastatic cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Siddiqui, F., Patel, M., Khan, M., et al.[2009]

Stereotactic body radiotherapy (SBRT) is primarily used for recurrent head and neck cancer, with usage rates ranging from 10% to 100%, while it is rarely applied to newly diagnosed cases (0-10%).

There is significant variability in treatment techniques and patient selection among 15 international institutions, including differences in target volume margins and fractionation regimens, which may impact treatment outcomes and safety, such as the risk of carotid blowout ranging from 3% to 20% in re-irradiation cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Karam, I., Yao, M., Heron, DE., et al.[2018]

Stereotactic radiotherapy (SBRT) shows promise in treating head and neck cancer (HNC), particularly in reirradiation settings, but there is currently insufficient evidence to support its use as a primary treatment option.

While SBRT carries risks such as carotid blow out syndrome, alternative treatment regimens may help mitigate these risks, highlighting the need for further research through large Phase III trials to establish its efficacy and safety in HNC.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer. Iqbal, MS., West, N., Richmond, N., et al.[2022]

Stereotactic body radiation therapy (SBRT) shows promise as a treatment for head and neck cancers, with early results indicating potential benefits.

However, patients with a history of prior external beam radiotherapy may experience serious acute and late side effects, highlighting the need for careful consideration of patient history when using SBRT.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic body radiotherapy for head and neck cancer: an addition to the armamentarium against head and neck cancer. Karam, I., Poon, I., Lee, J., et al.[2015]

Stereotactic body radiotherapy (SBRT) is a safe and feasible treatment option for patients with recurrent squamous cell carcinoma of the head and neck, showing minimal toxicities and no severe treatment-related side effects (grade 4 or 5).

In a study of 85 patients, SBRT resulted in a 1-year local control rate of 51.2% and a median overall survival of 11.5 months, with better outcomes observed in patients receiving doses of 35 Gy or higher.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Rwigema, JC., Heron, DE., Ferris, RL., et al.[2019]

Stereotactic Body Radiotherapy (SBRT) is a highly effective and well-tolerated treatment for recurrent and previously irradiated head and neck tumors, offering a favorable alternative to traditional salvage therapies.

SBRT provides the benefits of a shorter treatment schedule and can be safely administered in an outpatient setting, making it a promising option for definitive treatment in select patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. Lim, CM., Clump, DA., Heron, DE., et al.[2015]

Single fraction stereotactic radiosurgery (SRS) demonstrated a one-year local control rate of 52.7% in 18 patients with recurrent head and neck cancers, suggesting it can be an effective treatment option for these challenging cases.

The median overall survival for patients treated with SRS was 25.4 months, although those with parotid gland tumors and squamous cell histology faced higher risks of disease progression and lower survival rates, indicating the need for careful patient selection.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single Fraction Stereotactic Radiosurgery for Retreatment of Skull Base Recurrent Head and Neck Malignancies. Patel, RA., Lock, D., Kim, T., et al.[2020]

Stereotactic body radiotherapy (SBRT) at doses up to 44 Gy was found to be safe for previously irradiated patients with squamous cell carcinoma of the head and neck, with no severe toxicities reported and only mild acute side effects in four patients.

The treatment showed a 17% objective response rate, with some patients experiencing stable disease for up to 4 months, suggesting that SBRT could be a viable option for reirradiation in this patient population, warranting further studies alongside other therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Heron, DE., Ferris, RL., Karamouzis, M., et al.[2022]

Stereotactic body radiotherapy (SBRT) was administered to 66 medically unfit patients with head and neck cancer, showing a 1-year local control rate of 73% and overall survival rate of 64%.

The treatment resulted in only two cases of grade 3 toxicity, indicating that SBRT is a relatively safe option that can effectively manage cancer while preserving the quality of life for patients who cannot undergo conventional therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. Gogineni, E., Rana, Z., Vempati, P., et al.[2021]

Stereotactic body radiotherapy (SBRT) demonstrated significant efficacy in treating head and neck tumors, with a local control rate of 94% for de novo tumors at 3 months, indicating it is a viable option for patients not suitable for surgery.

Patients reported improved quality of life after treatment, with pre-treatment scores showing a trend towards significance (p=0.05), suggesting that SBRT not only controls tumor growth but also enhances the well-being of elderly and frail patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients. Khan, L., Tjong, M., Raziee, H., et al.[2022]

The combination of stereotactic body radiation therapy (SBRT) with the anti-PD-1 drug nivolumab was found to be safe and did not delay surgery in 21 patients with advanced head and neck cancer, meeting the primary safety endpoint of the study.

This treatment approach resulted in a high major pathological response (mPR) rate of 86% and a pathological complete response (pCR) rate of 67%, indicating that adding SBRT may enhance the effectiveness of immunotherapy in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. Leidner, R., Crittenden, M., Young, K., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10999469/

Stereotactic ablative radiotherapy for treating primary head ...

To summarize, with median 1-year OS rates of 40–55 % and acceptable overall severe toxicity rates, usually below 10 %, SABR has advanced into a reasonable ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38590327/

Stereotactic ablative radiotherapy for treating primary head ...

Conclusions: SABR is an innovative, effective and promising treatment modality for small targets, especially in near proximity to organs at risk ...

3.

sciencedirect.com

sciencedirect.com/science/article/pii/S2452109420303584

Stereotactic Radiation Therapy for De Novo Head and ...

OS across all studies were as follows: 1 year 75.9% (75.1%-76.6%), 2 year 61.1% (60.3%-61.9%), 3 year 50.0% (48.8%-51.4%), and 41.5% (39.7%-43.3%) at 4 years ( ...

4.

frontiersin.org

frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00077/full

Stereotactic Radiosurgery and Stereotactic Body Radiation ...

Results: Clinical outcomes and costs of SRS and SBRT were compared to other therapies for treatment of cancer in the brain, spine, lung, prostate, and pancreas.

5.

mdpi.com

mdpi.com/2072-6694/16/5/851

Stereotactic Body Radiotherapy for Extracranial ...

Overall survival was 80.1% and 60.7% at 1 and 2 years, respectively. Included studies were heterogeneous and of poor quality, highlighting a ...

6.

jamanetwork.com

jamanetwork.com/journals/jamaoncology/fullarticle/2773455

Safety and Survival Rates Associated With Ablative ...

The findings of this study suggest that stereotactic ablative radiotherapy is generally safe and well tolerated in the oligometastatic setting.

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S2452109422002299

Efficacy and Safety of Stereotactic Body Radiation Therapy ...

Conclusions. SBRT provided durable LC for pediatric and AYA patients with cancer with minimal severe toxicities. Dose escalation may result in improved LC for ...

8.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC7689573/

Safety and Survival Rates Associated With Ablative ...

The findings of this study suggest that stereotactic ablative radiotherapy is generally safe and well tolerated in the oligometastatic setting.

9.

stanfordhealthcare.org

stanfordhealthcare.org/medical-treatments/s/stereotactic-body-radiation-therapy.html

Stereotactic Ablative Radiotherapy (SABR/SBRT)

High effectiveness and accuracy. For most indications, local tumor control rates of 90% can be achieved. · Non-invasive. · Convenient, outpatient service.